Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 19/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932184 | 0.89 | CCR2 (0.53) | CCR2MAPT | |
| SCHEMBL9932375 | 0.89 | CCR2 (0.56) | CCR2 | |
| SCHEMBL9966186 | 0.87 | CCR2 (0.55) | CCR2 | |
| SCHEMBL9931836 | 0.83 | CCR2 (0.68) | CCR2 | |
| SCHEMBL9932290 | 0.81 | CCR2 (0.65) | CCR2 | |
| SCHEMBL9932609 | 0.79 | CCR2 (0.65) | CCR2 | |
| SCHEMBL9966192 | 0.78 | CCR2 (0.54) | CCR2 | |
| SCHEMBL9932251 | 0.78 | CCR2 (0.53) | CCR2 | |
| SCHEMBL3091669 | 0.77 | CCR2 (0.56) | CCR2 | |
| SCHEMBL9966151 | 0.77 | CCR2 (0.63) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651957-B1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-02-18 | — | — | EP | claimed |
| EP-2651957-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-8518913-B2 | Phosphorous derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20120157413-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082568-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| EP-2651957-B1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2651957-B1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-8518913-B2 | Phosphorous derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518913-B2 | Phosphorous derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518913-B2 | Phosphorous derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120157413-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157413-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157413-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082568-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157413-A1 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CCR5, CXCR3, CXCR2 | CCR2 7/4885MAPT 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.